RXT vs. SYRE

Last updated Apr 1, 2026

Compare and contrast key facts about Rackspace Technology, Inc. (RXT) and Spyre Therapeutics Inc. (SYRE).

Performance

RXT vs. SYRE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rackspace Technology, Inc. (RXT) and Spyre Therapeutics Inc. (SYRE). The values are adjusted to include any dividend payments, if applicable.

RXT vs. SYRE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
RXT Rackspace Technology, Inc.	0.92%	-56.07%	10.50%	-32.20%	-78.10%	-29.33%	16.29%
SYRE Spyre Therapeutics Inc.	53.97%	40.72%	8.18%	91.33%	-90.53%	-39.64%	13.40%

Fundamentals

Market Cap RXT : $239.27M SYRE : $17.45B
EPS RXT : -$0.94 SYRE : -$1.00
PS Ratio RXT : 0.09 SYRE : 86.80
Total Revenue (TTM) RXT : $2.69B SYRE : $90.49M
Gross Profit (TTM) RXT : $506.40M SYRE : $0.00
EBITDA (TTM) RXT : $110.40M SYRE : -$173.86M

Returns By Period

In the year-to-date period, RXT achieves a 0.92% return, which is significantly lower than SYRE's 53.97% return.

RXT

• 1D: -2.02%
• 1M: -49.75%
• YTD: 0.92%
• 6M: -30.51%
• 1Y: -42.02%
• 3Y*: -19.53%
• 5Y*: -47.68%
• 10Y*: —

SYRE

• 1D: 11.05%
• 1M: 17.28%
• YTD: 53.97%
• 6M: 200.95%
• 1Y: 212.61%
• 3Y*: 90.90%
• 5Y*: -24.14%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RXT vs. SYRE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXT

RXT Risk / Return Rank: 43
RXT Sharpe Ratio Rank: 34
RXT Sortino Ratio Rank: 73
RXT Omega Ratio Rank: 65
RXT Calmar Ratio Rank: 25
RXT Martin Ratio Rank: 19

SYRE

SYRE Risk / Return Rank: 95
SYRE Sharpe Ratio Rank: 97
SYRE Sortino Ratio Rank: 94
SYRE Omega Ratio Rank: 91
SYRE Calmar Ratio Rank: 96
SYRE Martin Ratio Rank: 96

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RXT vs. SYRE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rackspace Technology, Inc. (RXT) and Spyre Therapeutics Inc. (SYRE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RXT	SYRE	Difference
Sharpe ratio Return per unit of total volatility	-0.17	3.11	-3.27
Sortino ratio Return per unit of downside risk	1.76	3.40	-1.64
Omega ratio Gain probability vs. loss probability	1.18	1.41	-0.23
Calmar ratio Return relative to maximum drawdown	-0.52	6.74	-7.27
Martin ratio Return relative to average drawdown	-1.19	17.68	-18.87
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RXT vs. SYRE - Sharpe Ratio Comparison

The current RXT Sharpe Ratio is -0.17, which is lower than the SYRE Sharpe Ratio of 3.11. The chart below compares the historical Sharpe Ratios of RXT and SYRE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RXT	SYRE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.17	3.11	-3.27
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	-0.14	-0.21
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	-0.11	-0.20

Correlation

The correlation between RXT and SYRE is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RXT vs. SYRE - Dividend Comparison

Neither RXT nor SYRE has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RXT vs. SYRE - Drawdown Comparison

The maximum RXT drawdown since its inception was -98.43%, roughly equal to the maximum SYRE drawdown of -99.11%. Use the drawdown chart below to compare losses from any high point for RXT and SYRE.

Drawdown Indicators

	RXT	SYRE	Difference
Max Drawdown Largest peak-to-trough decline	-98.43%	-99.11%	+0.68%
Max Drawdown (1Y) Largest decline over 1 year	-77.65%	-23.82%	-53.83%
Max Drawdown (5Y) Largest decline over 5 years	-98.43%	-98.74%	+0.31%
Current Drawdown Current decline from peak	-96.24%	-83.17%	-13.07%
Average Drawdown Average peak-to-trough decline	-71.44%	-62.41%	-9.03%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.07%	10.25%	+23.82%

Volatility

RXT vs. SYRE - Volatility Comparison

Rackspace Technology, Inc. (RXT) has a higher volatility of 29.87% compared to Spyre Therapeutics Inc. (SYRE) at 19.85%. This indicates that RXT's price experiences larger fluctuations and is considered to be riskier than SYRE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RXT	SYRE	Difference
Volatility (1M) Calculated over the trailing 1-month period	29.87%	19.85%	+10.02%
Volatility (6M) Calculated over the trailing 6-month period	149.28%	47.44%	+101.84%
Volatility (1Y) Calculated over the trailing 1-year period	255.03%	69.73%	+185.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	136.93%	178.69%	-41.76%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	130.17%	136.54%	-6.37%

Financials

RXT vs. SYRE - Profitability Comparison

The chart below illustrates the profitability comparison between Rackspace Technology, Inc. and Spyre Therapeutics Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RXT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Rackspace Technology, Inc. reported a gross profit of 120.40M and revenue of 682.80M. Therefore, the gross margin over that period was 17.6%.

SYRE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Spyre Therapeutics Inc. reported a gross profit of 45.25M and revenue of 90.49M. Therefore, the gross margin over that period was 50.0%.

RXT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Rackspace Technology, Inc. reported an operating income of -3.30M and revenue of 682.80M, resulting in an operating margin of -0.5%.

SYRE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Spyre Therapeutics Inc. reported an operating income of -57.17M and revenue of 90.49M, resulting in an operating margin of -63.2%.

RXT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Rackspace Technology, Inc. reported a net income of -32.70M and revenue of 682.80M, resulting in a net margin of -4.8%.

SYRE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Spyre Therapeutics Inc. reported a net income of -62.53M and revenue of 90.49M, resulting in a net margin of -69.1%.